Introduction
============

Cardiovascular disease (CVD) represents the major source of morbidity and is a leading cause of death in uremic patients on chronic hemodialysis.[@b1-vhrm-8-187] From nontraditional CVD risk factors in dialysis patients, a malnutrition-inflammation complex syndrome (MICS) has been postulated to play a role in the etiology of premature CVD in hemodialysis patients.[@b2-vhrm-8-187] Thus, there is considerable interest in finding appropriate interventions for the MICS in this population.

Protein energy malnutrition is highly prevalent in dialysis patients which negatively impacts prognosis. Protein energy malnutrition is implicated in a complex syndrome caused by nutritional and non-nutritional factors such as deficient food ingestion secondary to uremia, dietary restriction, chronic inflammatory state, and increased catabolism related to treatment modalities, nutrients loss in dialysate, and metabolic acidosis.[@b3-vhrm-8-187] Numerous studies have demonstrated that protein supplementation alone may improve protein metabolism and nutritional parameters and therefore improve clinical outcomes.[@b4-vhrm-8-187]--[@b6-vhrm-8-187] Meanwhile, causes of inflammation are multifactorial including exposure of blood to dialyzer membranes or tubing, infection on vascular access, reduced antioxidants, and increased oxidative stress.[@b3-vhrm-8-187],[@b7-vhrm-8-187] Therefore, in order for a nutritional intervention to be most effective, it should be targeted at improving protein status and have anti-inflammatory properties.[@b8-vhrm-8-187]

There is a growing scientific interest in the application of omega-3 fatty acids as a means to prevent CVD in dialysis patients. Omega-3 fatty acids have been postulated to reduce pro-inflammatory response, confer antithrombotic properties, improve lipid levels (particularly triglycerides), and improve endothelial function.[@b9-vhrm-8-187]--[@b12-vhrm-8-187] To date, there is no well-established recommendation on omega-3 fatty acid supplementation in the dialysis population despite the fact that these patients have lower omega-3 intake[@b13-vhrm-8-187] and plasma levels.[@b14-vhrm-8-187] Some of the studies published used supraphysiological doses of omega-3 (\>3 g/day) which required a high number of capsules and may have been difficult to consume long term.[@b15-vhrm-8-187] Moreover, there may be barriers to compliance with this type of nutritional intervention, especially when the study population includes non-Caucasian races, low income groups, and the unemployed.[@b16-vhrm-8-187] Some of the clinical studies relied only on subjective methods such as pill counting to measure compliance.[@b17-vhrm-8-187],[@b18-vhrm-8-187]

Therefore, we performed a pilot study to investigate the technical feasibility of "directly observed treatment" of nutritional supplementation administered during regular dialysis sessions. Secondary outcomes included observations on nutritional and inflammatory status of hypoalbuminemic patients undergoing hemodialysis. We hypothesized that a combination of protein and omega-3 supplementation would be more effective than protein supplementation alone in improving nutritional and inflammatory status.

Methods
=======

Patients
--------

Patients who were undergoing routine hemodialysis treatment at the Great Lake Dialysis Clinic in Detroit, MI, were screened (n = 105). Selection criteria included serum albumin levels not meeting the outcome goal of the Kidney Disease Outcome Quality Initiative (KDOQI) guidelines[@b19-vhrm-8-187] (≤3.9 g/ dL), age greater than 18 years, and ongoing dialysis treatment for at least 3 months prior to the study. Patients who were residents of nursing homes, receiving intradialytic parenteral nutrition or tube feeding, undergoing 8 hours of dialysis treatment, undergoing nocturnal dialysis, serum albumin \> 3.9 g/dL, or who had fish allergies were excluded.

Study design and procedures
---------------------------

The present study was approved by the Human Ethics Committee of Wayne State University and the Human Investigation Committee of Great Lakes Dialysis. Informed written consent was obtained from all patients. Eligible subjects (n = 63) were randomized into two groups; placebo + protein supplement (placebo, n = 32) and omega-3 + protein supplement (omega-3, n = 31). Patients, care givers, and investigators were blinded from group assignments. The study lasted 6 months.

Nutritional intervention and compliance
---------------------------------------

The nutritional intervention provided comprised two components. Both treatment groups received a blend of 30 mL liquid protein supplement (Proteinex^®^; Llorens Pharmaceuticals Inc, Miami, FL) in 60 mL of apple juice providing 100 kcal, 18 g protein, and 8 g carbohydrate (specifically, 30 mL of Proteinex provides 18 g of protein hydrolysate \[72 kcals\], with 1440 mg of L-arginine, 540 mg of L-leucine, 420 mg of L-phenylalanine, 132 mg of L-histidine, 780 mg of L-lysine, 360 mg of L-isoleucine, 132 mg of L-methionine, and 66 mg of L-tryptophan). Additionally, subjects were given four capsules of either omega-3 or placebo, formulated by Twin Rivers Technologies (Quincy, MA). Each of the omega-3 capsules contained 150 mg of docosahexaenoic acid (DHA) and 450 mg of eicosapentaenoic acid (EPA; total DHA 600 mg, total EPA 1800 mg), while the other capsule was a placebo comprised of olive oil. Analysis of omega-3 and placebo capsules is presented in [Table 1](#t1-vhrm-8-187){ref-type="table"}. Both protein and capsules were given to the patients three times a week after their regular dialysis session for a total duration of 6 months. Compliance was ascertained by administering the supplements during the patients' dialysis session with close monitoring by nurses. Tolerability and side effects of supplements were recorded by registered nurses and hospitalization rates were also monitored.

Blood sampling and laboratory measures
--------------------------------------

The study flow chart is shown in [Figure 1](#f1-vhrm-8-187){ref-type="fig"}. Approximately 20 mL of fasting blood sample was taken prior to the dialysis session. Plasma samples intended for lipid analysis were isolated from blood by centrifugation at 3000 rpm for 20 minutes at 4°C and were kept at 4°C to be analyzed on the following day. Blood samples for nuclear factor kappa B (NFκB) were processed immediately to obtain mononuclear cell extract using the Ficoll-Paque method[@b20-vhrm-8-187] and the extract was kept at −80°C until further analysis. Serum samples for common renal profiles (serum albumin, blood-urea-nitrogen, creatinine, hemoglobin) were sent to Satellite Laboratory Services (Redwood City, CA) for analysis and were measured using standard automated laboratory techniques.

### Lipids analysis

Total cholesterol, high density lipoprotein (HDL) cholesterol, and triacylglycerol (TAG) in the plasma were determined by enzymatic reaction using kits purchased from Pointe Scientific Inc (Canton, MI). Low density lipoprotein (LDL) cholesterol was calculated using the Friedwald equation (LDL-C = total cholesterol minus HDL-C minus TAG/5). LDL-C to HDL-C ratio was calculated by dividing LDL-C by HDL-C values.

### Inflammatory markers

Serum C-reactive protein (CRP) was analyzed by an independent laboratory (DMC Laboratory, Detroit, MI) using an immunoturbidimetric method. Activated NFκB was measured from the nuclear extracts using a TransAm chemiluminescent (p65) kit purchased from Active Motif (Carlsbad, CA) using the procedure described by the manufacturer. Nutritional indicators Serum albumin was measured by the bromocresol green method using standard automated laboratory techniques. Normalized protein nitrogen appearance (nPNA) was calculated according to K/DOQI guidelines (2000).[@b19-vhrm-8-187] The malnutrition-inflammation score (MIS) questionnaire[@b21-vhrm-8-187] was also administered prior to (baseline), during (month 2) and at the end of the study (month 6). MIS is a quantitative scoring system that comprises ten components related to patients' medical history, physical exam, body mass index (BMI), and laboratory parameters, which has been reported to be a useful tool to predict dialysis outcome, malnutrition, and inflammatory status.[@b22-vhrm-8-187]--[@b24-vhrm-8-187] MIS was performed and calculated by a single person, a registered dietitian, to minimize interobserver variability.

Statistical analysis
--------------------

The minimum sample size for each group was n = 31, which was estimated at a power of 80% and α = 0.05 for a two-arm parallel study to detect a 0.2 g/dL difference in serum albumin. Results were analyzed using intention to treat. All study participants were maintained in the treatment groups to which they were randomized regardless of post randomization withdrawal and any missing values reported accordingly. Categorical data are reported as number and percentage, while continuous data are reported as mean ± standard deviation (SD) or as otherwise stated. Independent *t*-test was used to determine differences in the variables of interest between the two groups at baseline. The difference between baseline and month 2 and between baseline and month 6 for each group were tested using a paired *t*-test. Data that were not normally distributed were tested using a nonparametric test. Statistical significance was set at α = 0.05. All statistical tests were performed using SPSS (v 16.0; IBM, Chicago, IL). As there was no significant difference between baseline and the 2-month values in any of the parameters measured, these are not discussed further (data not shown).

Results
=======

Demographic profiles
--------------------

The inclusion criteria were met by 69 patients and 63 agreed to participate. Subjects were randomized based on albumin levels, and with the exception of gender distribution, there were no significant differences in age, duration on dialysis, BMI, and prevalence of existing comorbidity (diabetes mellitus) or indicators of dialysis adequacy (Kt/v) between the two groups ([Table 2](#t2-vhrm-8-187){ref-type="table"}). The study population was homogenously comprised of African-American ethnicities with no difference in income between groups.

Tolerability, side effects, and compliance
------------------------------------------

Over the course of the study, four patients died due to (a) cerebrovascular accident (placebo group, n = 1), (b) diabetic infection (omega-3 group, n = 1) and (c) CVD (one patient from each group). There were no other adverse events reported (ie, a life-threatening adverse effect, inpatient hospitalization or prolongation of existing hospitalization, or a persistent or significant disability/incapacity), over the course of the study. No discernible "fishy" smells were reported by any of the patients with regards to capsule assignment. Two patients complained they could not swallow the pills (placebo group) and withdrew from the study ([Figure 1](#f1-vhrm-8-187){ref-type="fig"}). Twenty-one patients (33%) were able to take 100% of the supplements provided during the 6-month study period. Sixty-seven percent of the patients (n = 22 in the omega-3 group and n = 21 in the placebo group) were able to take greater than 80% of the supplements. The principal reason for lack of compliance was subjects who missed their scheduled dialysis sessions.

Effects on lipid profiles
-------------------------

One subject was excluded from the analysis due to high TAG levels (478 mg/dL) as the Friedwald equation for LDL-C estimation is not reliable when TAG levels exceed 400 mg/dL.[@b25-vhrm-8-187] Total cholesterol was significantly reduced over the 6 months intervention in both groups (*P* \< 0.001; [Table 3](#t3-vhrm-8-187){ref-type="table"}). At the end of 6 months, the reduction in total cholesterol in the omega-3 group (−37 ± 32 mg/dL) was approximately 50% greater than the reduction seen in the placebo group (−21 ± 26 mg/dL, *P* = 0.057). While HDL-C levels were increased at month-6 compared to baseline in both groups (*t* = −4.077, *P* = 0.000 and *t* = −3.410, *P* = 0.004, respectively), there was no significant difference between groups (*P* = 0.531). LDL-C was reduced in both groups ( omega-3 group: *t* = 6.083, *P* = 0.000, placebo group: *t* = 4.200, *P* = 0.000) at month-6 compared to baseline, however, no significant differences between the two groups were noted at the end of the study (*P* = 0.092). The LDL-C/HDL-C ratios were significantly improved in both groups compared to baseline (omega-3 group: *t* = 5.875, *P* = 0.000, placebo group: *t* = 4.683, *P* = 0.000). After 6 months, the omega-3 group had a significantly larger reduction in LDL-C/HDL-C ratio compared to the placebo group (−1.3 ± 1.1 versus −0.7 ± 0.8, *P* = 0.043). Compared to baseline, TAG levels did not change significantly in the placebo group (*P* = 0.561), while there was a tendency for a decline in the omega-3 group (*P* = 0.064).

Effects on nutritional parameters
---------------------------------

Serum albumin and other nutritional indices are presented in [Table 4](#t4-vhrm-8-187){ref-type="table"}. Serum albumin at the end of the study was comparable to the values observed at baseline in both the omega-3 (*t* = −1.895, *P* = 0.070) and placebo (*t* = −0.314, *P* = 0.756) groups. Comparison between both groups showed no significant difference (*P* = 0.295). Similarly, no changes were observed in MIS score, nPNA, and BMI following the intervention within or between the groups. Additionally, hemoglobin levels were not changed following intervention in both groups (omega-3 group: *t* = 1.100, *P* = 0.282, placebo group: *t* = −0.731, *P* = 0.471).

Effects on inflammatory indicators
----------------------------------

The NFκB levels observed after 6 months in the omega-3 and placebo groups were similar to baseline values ([Table 5](#t5-vhrm-8-187){ref-type="table"}). Additionally, mean differences (month-6 minus baseline) between omega-3 and placebo groups were not significantly different (*P* = 0.134). With regards to CRP levels, mean values showed a significant elevation in the placebo group (*t* = −2.158, *P* = 0.040) but not the omega-3 group (*t* = −0.582, *P* = 0.565) over 6 months. However these differences were not apparent when median CRP values were compared. Additionally, there was a significant inverse association between CRP and albumin levels across both groups (r = −0.261, *P* = 0.049).

Discussion
==========

Our study tested the potential of a combination of protein and omega-3 supplementation to improve nutritional and inflammatory markers in chronic hemodialysis patients. To increase compliance the supplements were administered during patients' routine dialysis session, three times per week ("directly observed treatment"). Directly observed treatment allowed for two-thirds of the subjects to receive more than 80% of the stated overall dose over a 6-month period. While compliance was excellent in patients who came in for regular dialysis sessions, the significant comorbidities within this patient population resulted in a large number of missed dialysis treatments (and hence missed supplementation).

We observed that serum albumin, one of the markers of nutritional status, was not improved significantly in either group following the intervention. This finding was in contrast to what has been reported in previous studies.[@b4-vhrm-8-187]--[@b6-vhrm-8-187] This may be explained by the fact that only a small number of patients were able to take all of the supplements provided to them (no missing days) during the study course (n = 21, 33.3%). Patients missed days of supplementation mostly due to frequent hospitalization or because they failed to show up for their routine dialysis treatment, ranging from 1--44 days. Therefore, this could potentially upset the effect of omega-3 and protein supplementation per se. Further analysis on a pool of patients who substantially completed the supplementation course (ie, taking \>80% of the supplements) showed marginal improvement in serum albumin at month-6 compared to baseline (3.6 ± 0.3 g/dL versus 3.7 ± 0.3 g/dL, *P* = 0.079) but no improvements were noted in those who took \<80% of the supplements (3.7 ± 0.2 vs 3.7 ± 0.4, *P* = 0.939). Interestingly, nPNA, an indicator of protein intake, remained constant in both groups despite protein supplementation. A similar study by Moretti et al[@b26-vhrm-8-187] also noted a similar trend, in which there were no changes in nPCR despite improvement in serum albumin in the protein group for the second 6 months.

Reduced protein intake and an increase in inflammatory response are two important factors that lead to a decrease in serum albumin.[@b27-vhrm-8-187] However, Kaysen et al[@b28-vhrm-8-187] had noted that low serum albumin in dialysis patients may be attributed to systemic inflammation rather than nutritional inadequacy as a causative factor per se. In relation to this, we also observed a significant inverse correlation between serum albumin and CRP which may indicate the influence of an inflammatory process on serum albumin levels. Friedman and Fadem[@b29-vhrm-8-187] suggested that serum albumin should be taken as a marker of illnesses rather than nutrition. This is due to the fact that serum albumin has a strong ability to predict mortality but rather limited prediction for nutritional status due to significant influence of non-nutrition causes (such as inflammation).

Many of the omega-3 fatty acid supplementation studies in dialysis patients have described various potential outcomes such as attenuating dyslipidemia, inflammation, and providing a cardioprotective effect. Moreover, there is substantial evidence for reducing TAG levels[@b30-vhrm-8-187]--[@b32-vhrm-8-187] even at a dosage as low as 1.5 g/day.[@b33-vhrm-8-187] As for plasma TAG, we saw a tendency for a reduction in TAG levels in both groups although in the omega-3 group statistical significance was marginal (*P* = 0.064). The large variation in the difference in TAG changes observed in the placebo group (−7 ± 61 mg/dL, *P* = 0.56, [Table 3](#t3-vhrm-8-187){ref-type="table"}) could be attributed to one subject with very high triglyceride concentrations. Upon removal of this subject the difference in TAG levels between the 6-month and baseline value was 1 ± 44 mg/dL, *P* = 0.89. Thus collectively these data suggest no change in TAG levels over 6 months in the placebo group, while there was a tendency for a reduction in TAG levels in the omega-3 group (−20 ± 44 mg/dL, *P* = 0.064). Previous studies[@b18-vhrm-8-187],[@b34-vhrm-8-187] which administered a higher amount of omega-3 per week, with varying percentages of EPA/DHA but with a shorter duration (4--8 weeks), also reported no changes in TAG levels. However, Bouzidi et al reported that a supplementation of 2.1 g omega-3 daily for 3 months among chronic kidney disease patients reduced TAG levels by 48%.[@b35-vhrm-8-187] However, it is important to note that the baseline TAG levels in their study were much higher than the current study (275 ± 58 mg/dL versus 123 ± 60 mg/dL in the omega-3 group). We postulate that, the baseline TAG levels (omega-3 group: 123 ± 60 mg/dL; placebo group: 104 ± 69 mg/dL) were within the normal levels and thus may not have been sufficiently elevated to achieve a significant reduction. Skulas-Ray et al reported that the extent of TAG lowering with omega-3 is a function of baseline TAG levels.[@b36-vhrm-8-187] Omega-3 supplementation resulted in better improvement in LDL-C/HDL-C ratios as compared to placebo which appeared to be due to a greater improvement in non-HDL-C. As for inflammatory markers, our results for CRP were inconclusive. While mean values in the placebo group increased over the 6-month period, this was not the case in the omega-3 group, in which CRP levels stayed the same. Thus omega-3, if not effective in attenuating inflammation, may be beneficial in preventing further increases in inflammatory status. However when the data were evaluated using median CRP values, these differences were no longer apparent suggesting the need for a larger sample size to definitively resolve this issue. Only a small number of studies have investigated the effects of omega-3 on inflammatory markers in hemodialysis patients. It is important to note that most of these studies are not comparable due to differences in study design, supplement dosage, EPA/DHA ratios and study duration. Saifullah et al showed that a supplementation of 1.3 g of oral EPA and DHA daily over a period of 3 months could modestly reduce CRP levels.[@b37-vhrm-8-187] However, a recent study using a larger dosage (2.08 g/day) but a shorter duration (10 weeks) showed no effects on serum systemic inflammatory markers (CRP, interleukin-6, tumor necrosis factor-α) and oxidative stress (malondialdehyde, total antioxidant capacity).[@b38-vhrm-8-187] In a prospective cohort study by Noori et al, the authors showed that a lower omega-6 to omega-3 ratio (\~6) was associated with decreased inflammation and overall mortality in hemodialysis patients which indicates the importance of n-6/3 polyunsaturated fatty acid ratios in the diet.[@b13-vhrm-8-187] However, our study was not designed to investigate the effects of this ratio per se.

NFκB, a key player in pathogenesis of inflammation, is stimulated by pro-inflammatory agents such as cytokines and CRP. Studies have shown that NFκB activation and subsequent activation of mononuclear cells triggers a process that causes myocardial inflammatory damage in hemodialysis patients.[@b39-vhrm-8-187],[@b40-vhrm-8-187] Interestingly, our data for translocation of activated NFκB to the nucleus showed no significant changes following the intervention within and between both groups even though we saw an increase in CRP levels in the placebo group. The latter may have been due to the fact that the baseline CRP values in the placebo group were lower than those assigned to the omega-3 group.

Study limitations
-----------------

We were restricted in our patient population to one dialysis clinic for this pilot study. While the lipid data suggested benefits of omega-3, the data for inflammatory markers was less clear cut. One plausible explanation for variation in inflammatory markers in the current study may be related to insufficient dosage/frequency of omega-3 supplementation as well as compliance (due to frequent hospitalization resulting in subjects missing dialysis sessions and therefore supplementation). There are several similar studies which also failed to report significant changes in inflammatory markers.[@b18-vhrm-8-187],[@b41-vhrm-8-187]--[@b43-vhrm-8-187] Studies which demonstrated a significant effect of omega-3 supplementation on inflammation indices are those with a higher dosage and more frequent administration of the supplement (9.1 to 21 g/week versus 7.2 g/week DHA + EPA in the current study) as well as reported higher patient compliance.[@b17-vhrm-8-187],[@b44-vhrm-8-187]--[@b46-vhrm-8-187] Another factor that could potentially explain the contradictory finding in our study with those studies is baseline levels of inflammatory markers. Omega-3 supplementation appears to be more effective in studies reporting higher baseline CRP (\>13.8 mg/dL) than those that did not.[@b17-vhrm-8-187],[@b38-vhrm-8-187],[@b44-vhrm-8-187]

Notwithstanding some of the limitations discussed above, ours is one of the few studies to report on the use of "directly observed treatment" of oral nutritional supplementation with protein and omega-3 in a cohort of hemodialysis patients. Our results suggest that "directly observed treatment" is technically feasible in hemodialysis patients and does not disrupt the normal dialysis schedule. The relatively large number of missed dialysis sessions due to hospitalizations, however, suggests that "directly observed treatment" should be used in the setting of both outpatient and inpatient dialysis sessions in order to optimize compliance. In addition, while emphasizing the huge progressive inflammatory burden in hemodialysis patients over time; this pilot study suggests that "directly observed treatment" with a combination of omega-3 and protein-based supplement (as opposed to a pure protein supplement) could have some beneficial effects on lipid profile and CRP progression. Further studies using a combination of outpatient and inpatient "directly observed treatment" of fish oil based nutritional supplementation are warranted.
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![Study's flow chart.\
**Notes:** All patients at the Great Lake Dialysis clinic (n = 105) were screened for eligibility. Sixty-nine patients met the inclusion criteria but six of them declined to participate. The remaining 63 patients were randomized into omega-3 and placebo groups and underwent intervention for 6 months. Seven additional subjects (placebo, n = 4; omega-3, n = 3) were excluded from data analysis due to death (n = 4, 2 from each group) or hospitalization (n = 3). Two patients voluntarily dropped out as they were unable to swallow the capsules but their data were included in the analysis (intent to treat).\
**Abbreviation:** MIS, malnutrition-inflammation score.](vhrm-8-187f1){#f1-vhrm-8-187}

###### 

Selected fatty acid composition of omega-3 and placebo capsule

            Omega-3 (g/100 g as FA)   Placebo (g/100 g as FA)
  --------- ------------------------- -------------------------
  C16:0     0.96                      13.86
  C16:1     0.35                      1.44
  C17:0     0.14                      0.07
  C17:1     --                        0.11
  C18:0     4.66                      2.73
  C18:1n9   8.88                      66.64
  C18:2n6   2.00                      11.42
  C18:3n3   0.77                      0.69
  C20:0     0.50                      0.43
  C20:1n9   --                        0.26
  C20:5n3   35.36                     --
  C21:5n3   1.70                      --
  C22:5n3   4.95                      --
  C22:6n3   24.31                     --
  SAFA      7.02                      17.26
  MUFA      15.21                     70.63
  PUFA      77.77                     12.11
  Omega-3   67.08                     0.69

**Abbreviations:** FA, fatty acids; SAFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.

###### 

Clinical and demographic characteristics of the study population

                             Omega-3 (n = 31)   Placebo (n = 32)   *P*-value
  -------------------------- ------------------ ------------------ -----------
  **Demographics**                                                 
  Age (years)                59 ± 13            58 ± 13            0.845
  Ethnicity                                                        
   African American (n, %)   30 (97)            32 (100)           --
   Caucasian (n, %)          1 (3)              0 (0)              --
  Gender (males, %)          20 (62.5)          12 (38.7)          0.059
  Income (\$ per month)      1015 ± 576         1148 ± 761         0.552
  **Clinical**                                                     
  Time on dialysis (years)   3.6 ± 2.9          3.3 ± 3.8          0.784
  BMI (kg/m^2^)              28.4 ± 8.3         26.9 ± 7.8         0.468
  Diabetes mellitus (n, %)   20 (62.5)          20 (64.5)          0.868
  Kt/v                       1.58 ± 0.29        1.63 ± 0.32        0.536
  Statin usage (n, %)        11 (35.5)          9 (28.1)           0.530
  CRP (mg/dL)                5.8 ± 9.2          4.9 ± 5.6          0.134

**Notes:** Differences in age, time on dialysis, BMI, Kt/v and income were tested using independent *t*-test. Baseline CRP levels are reported in median ± interquartile range. Differences were tested using Mann--Whitney rank-sum test. Differences in gender, diabetes mellitus, and statin treatment were tested using chi-square. *P* \< 0.05 is considered significant.

**Abbreviations:** BMI, body mass index; Kt/v, index of dialysis adequacy; CRP, C-reactive protein.

###### 

Means and standard deviations of lipid profiles (TC, HDLC, LDLC, and TAG) at baseline and month-6

                       Placebo (n = 26)   Omega-3 (n = 28)   *P* overall                                                               
  -------------------- ------------------ ------------------ ---------------- ------- ----------- ----------- ---------------- ------- -----------
  **Lipid profiles**                                                                                                                   
  TC (mg/dL)           159 ± 49           138 ± 42           **−21 ± 26**     0.000   176 ± 36    139 ± 29    **−37 ± 32**     0.000   **0.057**
  HDLC (mg/dL)         44 ± 13            49 ± 11            **+5 ± 8**       0.004   41 ± 14     47 ± 16     **+6 ± 8**       0.000   **0.531**
  LDLC (mg/dL)         94 ± 42            69 ± 35            **−25 ± 27**     0.000   108 ± 34    71 ± 29     **−39 ± 33**     0.000   **0.092**
  TAG (mg/dL)          104 ± 69           96 ± 68            **−7 ± 61**      0.561   123 ± 60    102 ± 53    **−20 ± 55**     0.064   **0.405**
  LDL-HDL ratio        2.2 ± 1.0          1.5 ± 0.9          **−0.7 ± 0.8**   0.000   3.0 ± 1.6   1.7 ± 1.0   **−1.3 ± 1.1**   0.000   **0.043**

**Notes:** All values are presented as mean ± SD. *P* values for each group derived from paired *t*-test between baseline versus month-6 comparison. Overall *P* values derived using independent *t*-test, tested for mean differences of lipid profiles parameters between omega-3 and placebo groups (bold face). Data excludes values from 7 subjects (placebo, n = 4; omega-3, n = 3) who died (n = 4, 2 from each group), or were hospitalized (n = 3), during the course of the study. One subject (placebo) was excluded due to extremely high TAG levels (478 mg/dL) as the Friedwald equation is not reliable when TAG levels exceed 400 mg/dL.

**Abbreviations:** TC, total cholesterol; HDLC, high density lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol; TAG, triacylglycerides; Diff, mean difference of month-6 minus baseline.

###### 

Means and standard deviations of nutritional status indicators (Ser alb, Hgb, MIS score, nPNA, and BMI) at baseline and month-6

                           Placebo (n = 27)   Omega-3 (n = 28)   *P* overall                                                                       
  ------------------------ ------------------ ------------------ ------------------ ------- ------------- ------------- ------------------ ------- -----------
  **Nutritional status**                                                                                                                           
  Ser alb (g/dL)           3.7 ± 0.2          3.8 ± 0.4          **0.0 ± 0.3**      0.756   3.6 ± 0.3     3.7 ± 0.3     **0.1 ± 0.3**      0.070   **0.295**
  Hgb (g/L)                11.0 ± 1.0         11.3 ± 1.7         **0.2 ± 1.7**      0.471   10.4 ± 1.1    10.8 ± 1.5    **0.3 ± 1.4**      0.282   **0.866**
  MIS score                7.6 ± 3.6          8.1 ± 4.0          **0.6 ± 4.0**      0.215   9.0 ± 3.6     9.1 ± 3.4     **0.4 ± 2.2**      0.408   **0.730**
  nPNA                     0.96 ± 0.38        0.91 ± 0.22        **−0.01 ± 0.23**   0.810   0.99 ± 0.29   0.87 ± 0.25   **−0.07 ± 0.45**   0.471   **0.598**
  BMI (kg/m^2^)            25.4 ± 5.6         25.1 ± 6.1         **0.3 ± 1.8**      0.327   28.1 ± 7.0    28.1 ± 7.2    **0.1 ± 1.0**      0.699   **0.500**

**Notes:** All values are presented as mean ± SD. *P* values for each group derived from paired *t*-test between baseline versus month-6 comparison. Overall *P* values derived using independent *t*-test, tested for mean differences of nutritional parameters between omega-3 and placebo groups (bold face). Data excludes values from 7 subjects (placebo, n = 4; omega-3, n = 3) who died (n = 4, 2 from each group) or were hospitalized (n = 3), during the course of the study.

**Abbreviations:** Ser alb, serum albumin; Hgb, hemoglobin; MIS, malnutrition inflammation score; nPNA, normalized protein equivalence of nitrogen appearance; BMI, body mass index; Diff, mean difference of month-6 minus baseline.

###### 

Means and standard deviations of inflammatory indicators (NFκB, CRP) at baseline and month-6

                    Placebo (n = 27)   Omega-3 (n = 28)   *P* overall                                       
  ----------------- ------------------ ------------------ ------------- ------------- ------------- ------- -----------
  NFκB (μg/mL)      2.48 ± 1.03        2.54 ± 1.14        0.703         2.52 ± 1.19   2.15 ± 0.4    0.129   **0.134**
  CRP (mg/dL)\*     6.6 ± 8.3          11.0 ± 13.9        0.040         13.1 ± 17.5   14.6 ± 19.7   0.565   **0.259**
  CRP (mg/dL)\*\*   4.9 ± 5.6          4.6 ± 12.0         0.034         5.8 ± 9.2     6.1 ± 14.0    0.412   **0.326**

**Notes:** NFκB value is presented as mean ± SD. CRP value is presented as \*mean ± SD and \*\*median ± IQR. *P* values for each group derived from either paired *t*-test (NFκB )/Wilcoxon rank sum test (CRP) between baseline versus month-6 comparison. Overall *P* values derived using either independent *t*-test/Mann--Whitney rank sum test, tested for mean differences of inflammatory parameters between omega-3 and placebo groups (bold face). Data excludes values from 7 subjects (placebo, n = 4; omega-3, n = 3) who died (n = 4, 2 from each group) or were hospitalized (n = 3), during the course of the study.

**Abbreviations:** NFκB, Nuclear factor kappa-light-chain enhancer of activated B cells; CRP, C-reactive protein.
